Sug­gest­ed by Bloomberg, blessed by an­a­lysts, could an M&A match with a cer­tain MS play­er be far off for block­buster-hun­gry Sanofi?

All the signs are right.

Sanofi CEO Paul Hud­son has an M&A war chest set aside from the sale of their Re­gen­eron stock. A few more strate­gic deals would add con­sid­er­able ex­cite­ment to the late-stage pipeline — Job 1 at a phar­ma gi­ant that long ago drift­ed to the unim­pres­sive side of Big Phar­ma and des­per­ate­ly wants out. Bloomberg re­ports that MS and im­mune dis­or­ders are in the crosshairs at the Paris-based multi­na­tion­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER